Skip to main content
. 2016 Sep 29;12(5):3836–3844. doi: 10.3892/ol.2016.5207

Figure 5.

Figure 5.

Wound healing, invasion and migration Transwell assays in cells treated with CXB. (A) Wounding healing (left and right panel, *P=0.039 and 0.035, respectively), (B) invasion Transwell (Matrigel) (left and right panel, *P=0.026 and 0.021, respectively) and (C) migration Transwell (without Matrigel) (left and right panel, *P=0.028 and 0.020, respectively) assays of human lung adenocarcinoma LTEP-A2 and A549 cells treated with CXB. *P<0.05 vs. cells not treated with CXB. CXB, celecoxib.